Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods – 2 July 2021

Overview

The Therapeutic Goods Act 1989 was enacted to provide a regulatory framework for therapeutic goods in Australia, ensuring their safety, quality, and efficacy. This Act was introduced to address the need for a comprehensive legislative approach to the control of therapeutic goods, including medicines, medical devices, and other related products. The Act empowers the Therapeutic Goods Administration (TGA) to regulate these goods through licensing, monitoring, and enforcement activities. The Parliament of Australia enacted this Act to safeguard public health by establishing stringent standards for the manufacture, importation, supply, and advertising of therapeutic goods. The policy objective is to ensure that only those therapeutic goods that meet safety, quality, and efficacy standards are available to the public, thereby protecting consumers from potential harm. On 2 July 2021, Katherine Clark, as a delegate of the Secretary of the Department of Health, published the revocation of a Licence to Manufacture Therapeutic Goods held by The Kirby Institute - UNSW Medicine. This revocation was made under section 41(1)(d) of the Therapeutic Goods Act 1989, at the request of the manufacturer, and serves as a formal administrative action taken by the Therapeutic Goods Administration to ensure compliance with the regulatory standards set forth in the Act. This action underscores the TGA's commitment to maintaining high standards of quality and safety in the manufacture of therapeutic goods in Australia.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods within Australia, encompassing a broad range of products including medicines, medical devices, blood, and tissues. This Act applies to persons and entities involved in the manufacturing, importation, supply, and advertising of therapeutic goods, with its jurisdictional reach extending across the Commonwealth of Australia. The Act provides a framework for ensuring that therapeutic goods are safe, of high quality, and perform as claimed, and it mandates that manufacturers and suppliers of therapeutic goods hold appropriate licences and adhere to specific standards. Notably, the Act includes provisions for the revocation of licences, such as the one held by The Kirby Institute - UNSW Medicine, which was revoked at the request of the manufacturer. This legislative instrument extends its application through subordinate instruments and regulations that further detail the requirements and standards for therapeutic goods. Exclusions and exemptions may apply to certain classes of goods or specific circumstances, but these are typically defined in the Act or in related subordinate legislation. The revocation of a licence, as exemplified in the case of The Kirby Institute - UNSW Medicine, signifies a significant action taken under the Act to maintain the integrity and safety of the therapeutic goods market in Australia.

Key Provisions

The Therapeutic Goods Act 1989 contains several key provisions that regulate the manufacture, supply, and distribution of therapeutic goods within Australia. Section 41(1)(d) (1) allows the Secretary to revoke a licence to manufacture therapeutic goods if the licence holder requests it, or if certain conditions are met that warrant such action. This section ensures that the Therapeutic Goods Administration (TGA) can maintain control over the quality and safety of therapeutic goods by revoking licences as necessary. The revocation process is a significant tool for the TGA in ensuring compliance with standards and maintaining public health protection. Under this Act, entities such as The Kirby Institute - UNSW Medicine, which held Licence No. MI-2020-LI-04908-1, are subject to stringent obligations and requirements. These include adherence to good manufacturing practices, maintaining proper records, and ensuring that all therapeutic goods produced meet the quality and safety standards set by the TGA. The revocation of their licence implies that The Kirby Institute - UNSW Medicine had either voluntarily requested the revocation or that there were circumstances necessitating such action by the Secretary. The revocation notice, signed by Katherine Clark, Delegate of the Secretary, specifies the details of the licence revocation and serves as an official notification to the public and relevant stakeholders. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can result in various offences and penalties. For instance, manufacturing therapeutic goods without a valid licence or contravening the terms of a licence can lead to criminal charges. Under section 41(1)(d) (2), the maximum penalties for contravening the Act include substantial fines and imprisonment. The exact penalties depend on the severity of the offence and can vary significantly. Additionally, civil consequences may include the imposition of fines, court orders, or other remedies aimed at ensuring compliance and preventing harm to consumers. The revocation of a licence to manufacture therapeutic goods, as seen in the case of The Kirby Institute - UNSW Medicine, has significant implications for the entity involved. It not only affects their ability to manufacture and supply therapeutic goods but also impacts their reputation and credibility within the industry. The public notification of such revocations serves as a deterrent to other entities and reinforces the importance of adhering to the regulatory standards set by the TGA. This legal framework ensures that therapeutic goods available in the Australian market are safe, effective, and of high quality, ultimately protecting public health.